Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system

Gut. 2020 May;69(5):877-887. doi: 10.1136/gutjnl-2018-317233. Epub 2019 Aug 28.

Abstract

Objective: Insulinomas and non-functional pancreatic neuroendocrine tumours (NF-PanNETs) have distinctive clinical presentations but share similar pathological features. Their genetic bases have not been comprehensively compared. Herein, we used whole-genome/whole-exome sequencing (WGS/WES) to identify genetic differences between insulinomas and NF-PanNETs.

Design: The mutational profiles and copy-number variation (CNV) patterns of 211 PanNETs, including 84 insulinomas and 127 NF-PanNETs, were obtained from WGS/WES data provided by Peking Union Medical College Hospital and the International Cancer Genome Consortium. Insulinoma RNA sequencing and immunohistochemistry data were assayed.

Results: PanNETs were categorised based on CNV patterns: amplification, copy neutral and deletion. Insulinomas had CNV amplifications and copy neutral and lacked CNV deletions. CNV-neutral insulinomas exhibited an elevated rate of YY1 mutations. In contrast, NF-PanNETs had all three CNV patterns, and NF-PanNETs with CNV deletions had a high rate of loss-of-function mutations of tumour suppressor genes. NF-PanNETs with CNV alterations (amplification and deletion) had an elevated risk of relapse, and additional DAXX/ATRX mutations could predict an increased relapse risk in the first 2-year period.

Conclusion: These WGS/WES data allowed a comprehensive assessment of genetic differences between insulinomas and NF-PanNETs, reclassifying these tumours into novel molecular subtypes. We also proposed a novel relapse risk stratification system using CNV patterns and DAXX/ATRX mutations.

Keywords: gene mutation; neuroendocrine tumours; pancreas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asymptomatic Diseases / classification
  • Biopsy, Needle
  • Diagnosis, Differential
  • Exome Sequencing
  • Female
  • Gene Dosage / genetics*
  • Humans
  • Immunohistochemistry
  • Insulinoma / classification
  • Insulinoma / genetics*
  • Male
  • Mutation
  • Neuroendocrine Tumors / classification
  • Neuroendocrine Tumors / genetics*
  • Nuclear Proteins / genetics
  • Pancreatic Neoplasms / classification
  • Pancreatic Neoplasms / genetics*
  • Risk Assessment
  • Whole Genome Sequencing / methods*

Substances

  • Nuclear Proteins